Effect of a new PPAR-gamma agonist, lobeglitazone, on neointimal formation after balloon injury in rats and the development of atherosclerosis

Atherosclerosis

Volumn 243, Issue 1, 2015, Pages 107-119

  Lim, Soo ^a,b   Lee, Kuy Sook ^a   Lee, Jie Eun ^a,b   Park, Ho Seon ^b   Kim, Kyoung Min ^a,b   Moon, Jae Hoon ^a,b   Choi, Sung Hee ^a,b   Park, Kyong Soo ^a,b   Kim, Young Bum ^a,c,d   Jang, Hak Chul ^a,b  

^a Seoul National University Bundang Hospital   (South Korea)

^b Seoul National University College of Medicine   (South Korea)

^c Seoul National University   (South Korea)

^d HARVARD MEDICAL SCHOOL   (United States)

Author keywords

Atherosclerosis; Endothelium; PPAR ; Vascular smooth muscle cells

Indexed keywords

ADIPONECTIN; APOLIPOPROTEIN E; C REACTIVE PROTEIN; INSULIN; LOBEGLITAZONE; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR ALPHA; 2,4 THIAZOLIDINEDIONE DERIVATIVE; CCL2 PROTEIN, MOUSE; CCL2 PROTEIN, RAT; CHOLESTEROL; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PYRIMIDINE DERIVATIVE; RELA PROTEIN, MOUSE; RELA PROTEIN, RAT; TUMOR NECROSIS FACTOR;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; ATHEROSCLEROSIS; CAROTID ARTERY INJURY; CELL ADHESION; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE PROGRESSION; CELL CYCLE S PHASE; CELL MIGRATION; CELL PROLIFERATION; CHOLESTEROL DIET; CONTROLLED STUDY; DOWN REGULATION; DRUG MEGADOSE; ENDOTHELIUM CELL; GENE INACTIVATION; GENE TRANSLOCATION; INSULIN RESISTANCE; LIPID DIET; LOW DRUG DOSE; MALE; MONOCYTE; NEOINTIMA; NONHUMAN; PRIORITY JOURNAL; RAT; VASCULAR SMOOTH MUSCLE CELL; AGONISTS; ANIMAL; AORTA; ATHEROSCLEROTIC PLAQUE; CAROTID ARTERY; CELL NUCLEUS; GENETICS; HUMAN; IMMUNOHISTOCHEMISTRY; KNOCKOUT MOUSE; METABOLISM; MOUSE; PATHOLOGY; RISK FACTOR; SPRAGUE DAWLEY RAT; UMBILICAL VEIN ENDOTHELIAL CELL;

ANIMALS; AORTA; APOLIPOPROTEINS E; ATHEROSCLEROSIS; C-REACTIVE PROTEIN; CAROTID ARTERIES; CELL ADHESION; CELL NUCLEUS; CELL PROLIFERATION; CHEMOKINE CCL2; CHOLESTEROL; DIET, HIGH-FAT; HUMAN UMBILICAL VEIN ENDOTHELIAL CELLS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICE, KNOCKOUT; NEOINTIMA; PLAQUE, ATHEROSCLEROTIC; PPAR GAMMA; PYRIMIDINES; RATS; RATS, SPRAGUE-DAWLEY; RISK FACTORS; THIAZOLIDINEDIONES; TRANSCRIPTION FACTOR RELA; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84941267873     PISSN: 00219150     EISSN: 18791484     Source Type: Journal    
DOI: 10.1016/j.atherosclerosis.2015.08.037     Document Type: Article

References (49)

1. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
2. Cunard R., Ricote M., DiCampli D., et al. Regulation of cytokine expression by ligands of peroxisome proliferator activated receptors. J. Immunol. 2002, 168:2795-2802.
3. Derosa G., Maffioli P. Peroxisome proliferator-activated receptor-gamma (PPAR-gamma) agonists on glycemic control, lipid profile and cardiovascular risk. Curr. Mol. Pharmacol. 2012, 5:272-281.
4. Hamblin M., Chang L., Fan Y., Zhang J., Chen Y.E. PPARs and the cardiovascular system. Antioxid. Redox Signal 2009, 11:1415-1452.
5. Law R.E., Goetze S., Xi X.P., et al. Expression and function of PPARgamma in rat and human vascular smooth muscle cells. Circulation 2000, 101:1311-1318.
6. Dubey R.K., Zhang H.Y., Reddy S.R., Boegehold M.A., Kotchen T.A. Pioglitazone attenuates hypertension and inhibits growth of renal arteriolar smooth muscle in rats. Am. J. Physiol. 1993, 265:R726-R732.
7. Wakino S., Kintscher U., Kim S., Yin F., Hsueh W.A., Law R.E. Peroxisome proliferator-activated receptor gamma ligands inhibit retinoblastoma phosphorylation and G1--> S transition in vascular smooth muscle cells. J. Biol. Chem. 2000, 275:22435-22441.
8. Goetze S., Xi X.P., Kawano H., et al. PPAR gamma-ligands inhibit migration mediated by multiple chemoattractants in vascular smooth muscle cells. J. Cardiovasc. Pharmacol. 1999, 33:798-806.
9. Ricote M., Li A.C., Willson T.M., Kelly C.J., Glass C.K. The peroxisome proliferator-activated receptor-gamma is a negative regulator of macrophage activation. Nature 1998, 391:79-82.
10. Jiang C., Ting A.T., Seed B. PPAR-gamma agonists inhibit production of monocyte inflammatory cytokines. Nature 1998, 391:82-86.
11. Jackson S.M., Parhami F., Xi X.P., et al. Peroxisome proliferator-activated receptor activators target human endothelial cells to inhibit leukocyte-endothelial cell interaction. Arterioscler. Thromb. Vasc. Biol. 1999, 19:2094-2104.
12. Corzo C., Griffin P.R. Targeting the peroxisome proliferator-activated receptor-gamma to counter the inflammatory milieu in obesity. Diabetes Metab. J. 2013, 37:395-403.
13. Phillips J.W., Barringhaus K.G., Sanders J.M., et al. Rosiglitazone reduces the accelerated neointima formation after arterial injury in a mouse injury model of type 2 diabetes. Circulation 2003, 108:1994-1999.
14. Hong H.K., Cho Y.M., Park K.H., Lee C.T., Lee H.K., Park K.S. Peroxisome proliferator-activated receptor gamma mediated inhibition of plasminogen activator inhibitor type 1 production and proliferation of human umbilical vein endothelial cells. Diabetes Res. Clin. Pract. 2003, 62:1-8.
15. Choi D., Kim S.K., Choi S.H., et al. Preventative effects of rosiglitazone on restenosis after coronary stent implantation in patients with type 2 diabetes. Diabetes Care 2004, 27:2654-2660.
16. Nissen S.E., Wolski K. Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes. N. Engl. J. Med. 2007, 356:2457-2471.
17. Loke Y.K., Kwok C.S., Singh S. Comparative cardiovascular effects of thiazolidinediones: systematic review and meta-analysis of observational studies. BMJ 2011, 342:d1309.
18. Dormandy J.A., Charbonnel B., Eckland D.J., et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive study (PROspective pioglitAzone Clinical Trial in macroVascular Events): a randomised controlled trial. Lancet 2005, 366:1279-1289.
19. Lincoff A.M., Wolski K., Nicholls S.J., Nissen S.E. Pioglitazone and risk of cardiovascular events in patients with type 2 diabetes mellitus: a meta-analysis of randomized trials. JAMA 2007, 298:1180-1188.
20. Mitka M. FDA eases restrictions on the glucose-lowering drug rosiglitazone. JAMA 2013, 310:2604.
21. Azoulay L., Yin H., Filion K.B., et al. The use of pioglitazone and the risk of bladder cancer in people with type 2 diabetes: nested case-control study. BMJ 2012, 344:e3645.
22. Koffarnus R.L., Wargo K.A., Phillippe H.M. Rivoglitazone: a new thiazolidinedione for the treatment of type 2 diabetes mellitus. Ann. Pharmacother. 2013, 47:877-885.
23. Kim J.W., Kim J.R., Yi S., et al. Tolerability and pharmacokinetics of lobeglitazone (CKD-501), a peroxisome proliferator-activated receptor-gamma agonist: a single- and multiple-dose, double-blind, randomized control study in healthy male Korean subjects. Clin. Ther. 2011, 33:1819-1830.
24. Kim S.G., Kim D.M., Woo J.T., et al. Efficacy and safety of lobeglitazone monotherapy in patients with type 2 diabetes mellitus over 24-weeks: a multicenter, randomized, double-blind, parallel-group, placebo controlled trial. PLoS One 2014, 9:e92843.
25. Jin S.M., Park C.Y., Cho Y.M., et al. Lobeglitazone and pioglitazone as add-ons to metformin for patients with type 2 diabetes: a 24-week, multicentre, randomized, double-blind, parallel-group, active-controlled, phase III clinical trial with a 28-week extension. Diabetes Obes. Metab. 2015, 17:599-602.
26. Lee J.H., Woo Y.A., Hwang I.C., et al. Quantification of CKD-501, lobeglitazone, in rat plasma using a liquid-chromatography/tandem mass spectrometry method and its applications to pharmacokinetic studies. J. Pharm. Biomed. Anal. 2009, 50:872-877.
27. Lee J.H., Noh C.K., Yim C.S., et al. Kinetics of the absorption, distribution, metabolism, and excretion of lobeglitazone, a novel activator of peroxisome proliferator-activated receptor gamma in rats. J. Pharm. Sci. 2015, 104:3049-3059.
28. Lim S., Jin C.J., Kim M., et al. PPARgamma gene transfer sustains apoptosis, inhibits vascular smooth muscle cell proliferation, and reduces neointima formation after balloon injury in rats. Arterioscler. Thromb. Vasc. Biol. 2006, 26:808-813.
29. Lim S., Moon M.K., Shin H., et al. Effect of S-adenosylmethionine on neointimal formation after balloon injury in obese diabetic rats. Cardiovasc. Res. 2011, 90:383-393.
30. Ansari B., Coates P.J., Greenstein B.D., Hall P.A. In situ end-labelling detects DNA strand breaks in apoptosis and other physiological and pathological states. J. Pathol. 1993, 170:1-8.
31. Schwartz R.S., Murphy J.G., Edwards W.D., Camrud A.R., Vliestra R.E., Holmes D.R. Restenosis after balloon angioplasty. A practical proliferative model in porcine coronary arteries. Circulation 1990, 82:2190-2200.
32. Ferns G.A., Avades T.Y. The mechanisms of coronary restenosis: insights from experimental models. Int. J. Exp. Pathol. 2000, 81:63-88.
33. Walsh K., Smith R.C., Kim H.S. Vascular cell apoptosis in remodeling, restenosis, and plaque rupture. Circ. Res. 2000, 87:184-188.
34. Lange M., Fujikawa T., Koulova A., et al. Arterial territory-specific phosphorylated retinoblastoma protein species and CDK2 promote differences in the vascular smooth muscle cell response to mitogens. Cell Cycle 2014, 13:315-323.
35. Hiesinger W., Cohen J.E., Atluri P. Therapeutic potential of Rb phosphorylation in atherosclerosis. Cell Cycle 2014, 13:352.
36. Rogers C., Welt F.G., Karnovsky M.J., Edelman E.R. Monocyte recruitment and neointimal hyperplasia in rabbits. Coupled inhibitory effects of heparin. Arterioscler. Thromb. Vasc. Biol. 1996, 16:1312-1318.
37. Moreno P.R., Bernardi V.H., Lopez-Cuellar J., et al. Macrophage infiltration predicts restenosis after coronary intervention in patients with unstable angina. Circulation 1996, 94:3098-3102.
38. Moreno P.R., Fallon J.T., Murcia A.M., et al. Tissue characteristics of restenosis after percutaneous transluminal coronary angioplasty in diabetic patients. J. Am. Coll. Cardiol. 1999, 34:1045-1049.
39. Welt F.G., Edelman E.R., Simon D.I., Rogers C. Neutrophil, not macrophage, infiltration precedes neointimal thickening in balloon-injured arteries. Arterioscler. Thromb. Vasc. Biol. 2000, 20:2553-2558.
40. Mori E., Komori K., Yamaoka T., et al. Essential role of monocyte chemoattractant protein-1 in development of restenotic changes (neointimal hyperplasia and constrictive remodeling) after balloon angioplasty in hypercholesterolemic rabbits. Circulation 2002, 105:2905-2910.
41. Kanters E., Pasparakis M., Gijbels M.J., et al. Inhibition of NF-kappaB activation in macrophages increases atherosclerosis in LDL receptor-deficient mice. J. Clin. Investig. 2003, 112:1176-1185.
42. Collins T., Read M.A., Neish A.S., Whitley M.Z., Thanos D., Maniatis T. Transcriptional regulation of endothelial cell adhesion molecules: NF-kappa B and cytokine-inducible enhancers. FASEB J. 1995, 9:899-909.
43. Ohshima T., Koga H., Shimotohno K. Transcriptional activity of peroxisome proliferator-activated receptor gamma is modulated by SUMO-1 modification. J. Biol. Chem. 2004, 279:29551-29557.
44. Lim S., Quon M.J., Koh K.K. Modulation of adiponectin as a potential therapeutic strategy. Atherosclerosis 2014, 233:721-728.
45. Lee S.H. Adipokine profiles and metabolic health. Endocrinol. Metab. Seoul 2015, 30:175-176.
46. Motoshima H., Wu X., Mahadev K., Goldstein B.J. Adiponectin suppresses proliferation and superoxide generation and enhances eNOS activity in endothelial cells treated with oxidized LDL. Biochem. Biophys. Res. Commun. 2004, 315:264-271.
47. Chappuis B., Braun M., Stettler C., et al. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study. Diabetes Metab. Res. Rev. 2007, 23:392-399.
48. Berneis K., Rizzo M., Stettler C., et al. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes. Expert Opin. Pharmacother. 2008, 9:343-349.
49. Tulis D.A. Rat carotid artery balloon injury model. Methods Mol. Med. 2007, 139:1-30.